Ensartinib
Showing 1 - 22 of 22
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Ensartinib
-
Beijing, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022
Non Small Cell Lung Cancer Trial (Ensartinib Hydrochloride)
Not yet recruiting
- Non Small Cell Lung Cancer
- Ensartinib Hydrochloride
- (no location specified)
Dec 15, 2022
Non Small Cell Lung Cancer Trial in Beijing (Ensartinib)
Recruiting
- Non Small Cell Lung Cancer
- Ensartinib
-
Beijing, Beijing, China
- +1 more
Aug 17, 2022
NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)
Available
- Non-Small Cell Lung Cancer
- ALK Gene Rearrangement Positive
- Ensartinib
-
Stanford, California
- +3 more
Oct 18, 2022
NSCLC Trial in Tianjin (Ensartinib, Placebo)
Recruiting
- Non-small Cell Lung Cancer
- Ensartinib
- Placebo
-
Tianjin, ChinaTianJin Medical University Cancer Institute & Hospital
Jul 13, 2022
NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Ensartinib
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Aug 4, 2022
Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)
Active, not recruiting
- Melanoma
- Ensartinib
- ALKATI by Customized Nanostring Assay
-
Middletown, New Jersey
- +3 more
Jan 25, 2022
Solid Tumor, NSCLC Metastatic Trial in Guanzhou (Ensartinib)
Recruiting
- Solid Tumor
- Non-Small Cell Lung Cancer Metastatic
- Ensartinib
-
Guanzhou, Guangdong, ChinaSun yat-sen Univerisity Cancer Center
Nov 22, 2021
NSCLC Trial in Shijiazhuang (Ensartinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- Ensartinib
-
Shijiazhuang, Hebei, ChinaJun Feng Liu
Feb 6, 2022
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 13, 2022
Advanced Solid Tumors, NSCLC Trial in United States (Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib))
Completed
- Advanced Solid Tumors
- Non-small Cell Lung Cancer
- Phase I: X-396 (ensartinib)
- Phase II: X-396 (ensartinib)
-
Duarte, California
- +13 more
Oct 4, 2021
NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Avitinib Maleate
- +13 more
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022
NSCLC Trial in Worldwide (X-396 (ensartinib), crizotinib)
Active, not recruiting
- Non-small Cell Lung Cancer
- X-396 (ensartinib)
- crizotinib
-
Phoenix, Arizona
- +122 more
Oct 21, 2022
Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto
Recruiting
- Malignant Solid Neoplasm
- +26 more
- Ensartinib
- +2 more
-
Birmingham, Alabama
- +121 more
Aug 24, 2022
Lung Cancer Trial in Shanghai (ensartinib capsules (test product), ensartinib capsules (reference product))
Completed
- Lung Cancer
- ensartinib capsules (test product)
- ensartinib capsules (reference product)
-
Shanghai, Shanghai, ChinaShanghai Public Health Clinical Center
Jul 22, 2019
Lung Cancer, ROS1 Gene Rearrangement Trial in Shanghai (X-396 Capsule)
Unknown status
- Lung Cancer
- ROS1 Gene Rearrangement
- X-396 Capsule
-
Shanghai, Shanghai, ChinaChest hospital affiliated to Shanghai jiao tong university
Jan 6, 2020
NSCLC Trial in Hangzhou (Ensartinib with fed or fasting)
Completed
- Non-Small Cell Lung Cancer
- Ensartinib with fed or fasting
-
Hangzhou, Zhejiang, ChinaThe 1st Phase Clinical Research Center of the Second Affiliated
Jul 22, 2019
ALK-POSITIVE NSCLC Trial in Nanjing (Ensartinib)
Unknown status
- ALK-POSITIVE NSCLC
- Ensartinib
-
Nanjing, Jiangsu Provence, ChinaJiangsu Province Hospital Affiliated to Nanjing Madical Universi
Jan 14, 2019
Nonsmall Cell Lung Cancer, Brain Metastases Trial (X-396(Ensartinib) Capsule)
Unknown status
- Nonsmall Cell Lung Cancer
- Brain Metastases
- X-396(Ensartinib) Capsule
- (no location specified)
Nov 22, 2018
NSCLC, Carcinoma, NSCLC Trial in New York (Ensartinib, Durvalumab)
Completed
- Non-small Cell Lung Cancer
- +2 more
- Ensartinib
- Durvalumab
-
New York, New YorkResearch Facility
Oct 25, 2018
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023
NSCLC Trial in Beijing (X-396 capsule)
Unknown status
- Non-Small Cell Lung Cancer
- X-396 capsule
-
Beijing, China
- +3 more
Dec 19, 2017